Emerging therapies targeting the delta-like ligand 3 (DLL3) in small cell lung cancer

Small cell lung cancer (SCLC) is an aggressive neuroendocrine carcinoma with a poor prognosis. Initial responses to standard-of-care chemo-immunotherapy are, unfortunately, followed by rapid disease recurrence in most patients. Current treatment options are limited, with no therapies specifically ap...

Descripción completa

Detalles Bibliográficos
Autores principales: Rudin, Charles M., Reck, Martin, Johnson, Melissa L., Blackhall, Fiona, Hann, Christine L., Yang, James Chih-Hsin, Bailis, Julie M., Bebb, Gwyn, Goldrick, Amanda, Umejiego, John, Paz-Ares, Luis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10290806/
https://www.ncbi.nlm.nih.gov/pubmed/37355629
http://dx.doi.org/10.1186/s13045-023-01464-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10290806/
https://www.ncbi.nlm.nih.gov/pubmed/37355629
http://dx.doi.org/10.1186/s13045-023-01464-y

Ejemplares similares